Trial Information
Inclusion Criteria:
- newly diagnosed of multiple myeloma.
- Age > 65 years
- ECOG <= 3
- Written informed consent given at the time of randomization
- Patients with age <= 65 but not eligible for high dose treatment with stem cells
support
Exclusion Criteria:
- ECOG > 3
- current neoplasm..
- contraindications to use thalidomide
- peripheral neurophaty
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label
Outcome Measure:
To assess the efficacy
Outcome Description:
To compare the percentage of response in term of complete response, partial response, minimal and stable disease in the 2 arms o treatment
Outcome Time Frame:
from 8 to 12 months
Safety Issue:
No
Authority:
Italy: Ethics Committee
Study ID:
MM03
NCT ID:
NCT01274403
Start Date:
Completion Date:
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Elderly patients
- Multiple Myeloma
- Neoplasms, Plasma Cell